Part D Overhaul: The Silver Lining Amid Very Dark Cloud Of US Drug Pricing Bill
Executive Summary
Senate version of a potential drug pricing overhaul in the US includes one silver lining for manufacturers: a re-design and update of the Part D drug benefit. Is there any chance of extracting that item for the very dark clouds around it?
You may also be interested in...
Cost Sharing Program In Part D From Coalition Of Cancer Drug Manufacturers Rebuffed By OIG
Federal watchdog group acknowledges proposed assistance program aligns with comments in a 2005 OIG advisory bulletin on patient assistance programs in Medicare Part D, but maintains the bulletin should not serve as a roadmap for a compliant program in this case.
President Bio-den? Executive Order Highlights Value Of Biotech – But Doesn’t Change Pricing Message
The White House is playing up a new initiative to support ‘biotechnology and biomanufacturing.’ The focus on innovation is always a welcome theme – but it does not signal any change in the emphasis on cutting drug pricing in the Biden Administration.
Pricing Reform Advocates Poised For ‘Rearguard Action’ By Industry If Legislation Prevails
Patient advocates are optimistic that ‘historic bill’ establishing price negotiation, inflation rebates and a spending cap in Medicare will pass into law.